SCNLF (Scancell Holdings) 3-Year Share Buyback Ratio: -8.30% (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNLF Scancell Holdings PLC SCNLF
21 GF Score
Price $0.13
! 1 Warning Sign
View Full Analysis

What is Scancell Holdings 3-Year Share Buyback Ratio?

Scancell Holdings SCNLF 21 3-Year Share Buyback Ratio is -8.30 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,189 Biotechnology companies, Scancell Holdings ranks better than 56.94% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Scancell Holdings's current 3-Year Share Buyback Ratio was -8.30%.

The historical rank and industry rank for Scancell Holdings's 3-Year Share Buyback Ratio or its related term are showing as below:

SCNLF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7   Med: -11.2   Max: -4.4
Current: -8.3

During the past 13 years, Scancell Holdings's highest 3-Year Share Buyback Ratio was -4.40%. The lowest was -28.70%. And the median was -11.20%.

SCNLF's 3-Year Share Buyback Ratio is ranked better than
56.94% of 1189 companies
in the Biotechnology industry
Industry Median: -11.7 vs SCNLF: -8.30

Scancell Holdings (OTCPK:SCNLF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Scancell Holdings 3-Year Share Buyback Ratio Related Terms


SCNLF vs VRTX, REGN, RVMD: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Scancell Holdings's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's 3-Year Share Buyback Ratio falls into.


SCNLF
21GF Score
Scancell Holdings PLC SCNLF
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -8.30 mean?
Scancell Holdings (SCNLF) has a 3-Year Share Buyback Ratio of -8.30 as of Oct. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #512 out of 1189 companies in the Biotechnology industry, placing it in the top 43.1%.
Is Scancell Holdings' 3-Year Share Buyback Ratio too high?
Scancell Holdings' current 3-Year Share Buyback Ratio is -8.30. Based on the distribution chart, Scancell Holdings ranks #512 out of 1189 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #512 out of 1189 companies for 3-Year Share Buyback Ratio. This puts Scancell Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Scancell Holdings and its competitors. Scancell Holdings's current 3-Year Share Buyback Ratio is -8.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current 3-Year Share Buyback Ratio of -8.30. The current 3-Year Share Buyback Ratio is -8.30. Scancell Holdings' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current 3-Year Share Buyback Ratio is -8.30 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
21GF Score

Get the complete analysis for SCNLF

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price